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1. Introduction
  The global pandemic of human immunodeficiency 
virus (HIV) infection has led to a dramatic upsurge in the 
prevalence of tuberculosis[1]. The rise in annual incidence 
of tuberculosis worldwide from an estimated 4 million in 
the pre-HIV era[2] to nearly 10 million in the post-HIV 
era[3] is a testimonial to the impact of HIV on tuberculosis. 
Tuberculosis is now one of the principal opportunistic 
infections seen in people living with HIV infection, and it 
is also a major cause of morbidity and the largest cause 
of mortality in this population[4]. Over one quarter of all 
acquired immunodeficiency syndrome (AIDS)-related 
deaths are now attributable to tuberculosis[5]; of these 
deaths, 99% occur in the developing world[6]. HIV infection 
is the single most powerful risk factor for an individual to 
develop tuberculosis in his lifetime[7]; the lifetime risk of 
contracting tuberculosis in an HIV-positive individual is 
30% or more as compared to 5%-10% in an HIV-negative 
individual[8].
  The central mechanism behind this augmented risk 
is of course immunosuppression, resulting principally 
from HIV induced CD4 lymphocyte destruction. Other 
mechanisms include CD8 lymphocyte depletion[9], up-
regulation of Mycobacterium tuberculosis (M. tuberculosis) 
entry receptors on macrophages[10], manipulation of 
macrophage bactericidal pathways by HIV[11], impairment of 
chemotaxis[12], altered Th1/Th2 balance[11] and diminished 
tumor necrosis factor (TNF)-mediated apoptotic response to 
M. tuberculosis infection[13].
  Impaired cell mediated immunity immediately hampers 
the body’s principal defense against both new infection 
Objective: To determine the relationship between tuberculosis and the degree of 
immunosuppression as determined by CD4 count. The impact of immunosuppression on the 
severity of tuberculosis was also studied. Methods: A retrospective analysis was performed in 
patients newly diagnosed with HIV infection and antiretroviral therapy (ART)-naive patients with 
known HIV seropositivity. All patients were diagnosed with active tuberculosis between January 
2008 and December 2010, based on review of their medical records. Patients on chemoprophylaxis 
for opportunistic infection were excluded. Pattern and severity of tuberculosis, associated 
stigmata of immunosuppression, and CD4 counts were noted. Results: Of 140 patients satisfying 
the inclusion criteria, 52 had mild tuberculosis with no other evidence of immunosuppression, 52 
had tuberculosis of variable severity with associated evidence of immunosuppression, and 36 had 
severe tuberculosis with no other evidence of immunosuppression. The CD4 count was highest 
in the first group [(109.2依99.9) cells/毺L] and least in the second group [(58.4依39.8) cells/毺L], 
and the difference was statistically significant (P=0.004). No statistical difference was observed 
in the CD4 count between those with mild tuberculosis and those with severe tuberculosis. 
Conclusions: In developing countries with a high prevalence of tuberculosis in the general 
population, the possibility of incidental tuberculosis in patients with HIV should always be 
considered. CD4 count does not appear to influence the severity of tuberculosis. The presence 
of concomitant evidence of immunosuppression in the form of category B and C conditions is 
indicative of underlying immunosuppression and associated with a significantly lower CD4 count.
 Kushal Naha et al./Asian Pacific Journal of Tropical Medicine (2013)320-324 321
with M. tuberculosis and reactivation of latent infection. 
This mechanism is also responsible for most of the other 
opportunistic infections seen in HIV-infected individuals. 
However, tuberculosis differs from these infections in that it 
is widely seen within the general population, especially in 
the developing world. Indeed, immunocompetent individuals 
constitute the majority of persons with active tuberculosis 
in these regions. This is one of the reasons why tubercular 
infection can occur at any level of CD4 count. An unspoken 
corrigendum of this fact is that taken alone, tuberculosis 
does not necessarily indicate immunosuppression in a given 
individual with HIV seropositivity.
  In addition to its impact on the risk of developing 
tuberculosis, HIV infection also influences the manifestation 
of tuberculosis. Extrapulmonary tuberculosis has been 
shown to occur with a higher frequency among HIV positive 
individuals as compared to the general population[14]. 
Once again, atypical and extrapulmonary presentations 
of tuberculosis can be attributed to HIV-induced 
impairment of the normal immune response, resulting in 
rapid dissemination of infection. Needless to say, such an 
argument presupposes that atypical, extrapulmonary and 
severe forms of tuberculosis should occur in persons with 
greater degrees of immunosuppression and correspondingly 
lower CD4 counts-a finding which is yet to be confirmed by 
large scale studies.
  This study was therefore designed to determine the 
relationship between tuberculosis and the degree of 
immunosuppression as determined by CD4 count and 
to explore the impact of additional clinical evidence 
of immunosuppression in the form of category B and C 
conditions. A secondary objective was to test the hypothesis 
that lower CD4 counts are associated with atypical, 
extrapulmonary and severe forms of tuberculosis.
2. Materials and methods
2.1. Study settings
  Kasturba Medical College (Manipal, India) is a major 
tertiary care centre in Southwestern India. The catchment 
area of this hospital corresponds to the district of Udupi in 
which it is located, along with the neighbouring districts 
of Uttara Kannada and Dakshina Kannada. The combined 
population of this region approximates 4.36 million 
individuals.
2.2. Patients
  A retrospective analysis was performed in patients newly 
diagnosed with HIV infection and antiretroviral therapy 
(ART)-naive patients with known HIV seropositivity, who 
were diagnosed with active tuberculosis between January 
2008 and December 2010, based on review of their medical 
records. Patients on chemoprophylaxis for opportunistic 
infection were excluded.
2.3. Diagnosis and typing of tuberculosis
  All patients were diagnosed with tuberculosis on the 
basis of one or more of the following criteria: sputum or 
tissue sample positivity for acid fast bacilli, isolation of 
M. tuberculosis in culture from sputum or tissue sample, 
radiological features suggestive of tuberculosis and positive 
skin tuberculin testing. The type of tuberculosis observed 
was noted for all patients. Tubercular lymphadenitis, 
pulmonary parenchymal tuberculosis, tubercular pleural 
effusion and tubercular peritonitis were considered as mild 
tuberculosis. Disseminated tuberculosis, i.e., involvement 
of more than one organ/organ system, tubercular meningitis, 
tuberculoma and military tuberculosis were considered as 
severe tuberculosis.
2.4. CD4 counting
  The presence of additional evidence of immunosuppression 
at the time of diagnosis of tuberculosis in the form of 
accompanying category B or C conditions[15] was also noted. 
CD4 counts were noted for all patients included in the 
study. The earliest CD4 count available for each patient 
that was performed at least 2 weeks after the diagnosis of 
tuberculosis and prior to initiation of antiretroviral therapy 
was considered for the purpose of the study, to avoid falsely 
depressed CD4 counts in acutely ill patients.
2.5. Statistical analysis
  All data was analysed using SPSS Statistics version 17.0 
(Chicago, USA). Continuous variables are presented as mean依
SD. Independent sample t-test and one way ANOVA were 
used to compare the means of variables between various 
patient subsets. P-values less than 0.05 were considered to 
indicate statistical significance.
3. Results
3.1. Distribution of forms of tuberculosis across patient subsets 
classified according to severity of tuberculosis and evidence of 
immunosuppression
  A total of 451 patients were either diagnosed to be HIV 
seropositive or known to be HIV-positive but ART-naive 
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and not on any form of chemoprophylaxis for opportunistic 
infection, during the study period. Of these patients, 140 
had active tuberculosis during the study period. Fifty-
two patients had a mild form of tuberculosis with no other 
evidence of immunosuppression (Subset A). Fifty-two 
patients had tuberculosis of any severity in association 
with other manifestations of immunosuppression (Subset B). 
Thirty-six patients had severe tuberculosis without any other 
evidence of immunosuppression (Subset C). The three subsets 
were comparable in baseline characteristics (Table 1).
  Overall, the commonest forms of tuberculosis, i.e., 
parenchymal pulmonary tuberculosis and tubercular 
lymphadenitis, were seen in 39 (27.9%) patients each, 
and disseminated tuberculosis was seen in 35 (25.0%) 
patients. The least common form of tuberculosis tubercular 
pericarditis was seen in only one (0.7%) patient.
  Analysis across the patient subsets showed that tubercular 
lymphadenitis and parenchymal pulmonary tuberculosis 
were also the commonest forms in the subset A, seen 
respectively in 26 (50.0%) and 20 (38.5%) patients. In the 
subset B, parenchymal pulmonary tuberculosis and 
disseminated lymphadenitis were seen in 19 (36.5%) and 
13 (25.0%) patients respectively. In the subset C, 26 (72.2%) 
patients had disseminated tuberculosis, while 4 (11.1%) 
patients had tubercular meningitis. These findings are 
detailed in Table 2.
Table 1
Comparison of baseline characteristics and CD4 counts between patients with active tuberculosis.
Patient subset Age (years) Male-to-female ratio CD4 count (cells/毺L)
Subset A 41.1依9.7 47:5 109.2依99.9
Subset B 38.7依7.4   36:16   58.4依39.8
Subset C 40.4依8.5   26:10   92.8依82.9
The patients in the subset A had a mild form of tuberculosis with no other evidence of immunosuppression; those in the subset B had tuberculosis 
of any severity associated with other manifestations of immunosuppression; and those in the subset C had severe tuberculosis without any other 
evidence of immunosuppression.
Table 2
Distribution of forms of tuberculosis across patient subsets. 
Patient Form of tuberculosis Number of patients Patient percentage (%)
Overall (n=140) Pulmonary parenchymal tuberculosis 39 27.9
Disseminated tuberculosis 39 27.9
Tubercular lymphadenitis 35 25.0
Tubercular meningitis   8   5.7
Tubercular effusion   7   5.0
Tuberculoma   5   3.6
Tubercular peritonitis   3   2.1
Miliary tuberculosis   3   2.1
Tubercular pericarditis   1   0.7
Subset A (n=52) Tubercular lymphadenitis 26 50.0
Pulmonary parenchymal tuberculosis 20 38.5
Tubercular effusion   5   9.6
Tubercular peritonitis   1   1.9
Subset B (n=52) Pulmonary parenchymal tuberculosis 19 36.5
Disseminated tuberculosis 13 25.0
Tubercular lymphadenitis   9 17.3
Tubercular meningitis   4   7.7
Tubercular effusion   2   3.8
Tubercular peritonitis   2   3.8
Tuberculoma   2   3.8
Miliary tuberculosis   1   1.9
Subset C (n=36) Disseminated tuberculosis 26 72.2
Tubercular meningitis  4 11.1
Tuberculoma  3   8.3
Miliary tuberculosis  2   5.6
Tubercular pericarditis  1   2.8
The patients in the subset A had a mild form of tuberculosis with no other evidence of immunosuppression; those in the subset B had tuberculosis 
of any severity associated with other manifestations of immunosuppression; and those in the subset C had severe tuberculosis without any other 
evidence of immunosuppression.
 Kushal Naha et al./Asian Pacific Journal of Tropical Medicine (2013)320-324 323
3.2. Comparison of CD4 counts between patient subsets
  The mean CD4 count was highest in the patients with 
miliary tuberculosis and lowest in the patient with 
tubercular pericarditis (Table 3). No significant correlation 
between the CD4 count and form of tuberculosis was seen 
(Table 4). The mean CD4 count was significantly higher 
in the subset A [(109.2依99.9) cells/毺L] than in the other 
two subsets (P=0.004). Interestingly, the subset C which 
presented with the most severe form of tuberculosis actually 
had a higher mean CD4 count [(92.8依82.9) cells/毺L] than the 
subset B which included a proportion of patients with the 
mild forms of disease [(58.4依39.8) cells/毺L]. Altogether, 10 
(7.14%) patients had CD4 counts greater than 200 cells/毺L.
4. Discussion
  While the role that HIV plays in increasing an individual’s 
risk of developing tuberculosis is clear, it is also important 
to note that the relationship between these two infections is 
bidirectional and mutually beneficial. Tuberculosis like any 
other opportunistic infection produces a state of continuous 
systemic inflammation resulting in overstimulation of the 
host immune system. The direct fallout is accelerated CD4 
lymphocyte turnover, augmenting viral replication and 
thus viremia[16]. Infection of adjacent CD4 lymphocytes 
and macrophages within tuberculous granulomas has 
also been suggested as a mechanism of accelerated viral 
replication[17]. Finally, M. tuberculosis has now been shown 
to directly promote viral replication through activation of the 
HIV-1 long terminal repeat[18,19]. A natural consequence of 
this synergism between HIV and tuberculosis has been to 
label any form of tuberculosis as an AIDS defining disease in 
people living with HIV infection[20].
  As shown by a careful review of available statistics, HIV 
is associated with a large proportion of tuberculosis in 
developed countries where the prevalence of tuberculosis 
was extremely low in the pre-HIV era, while the situation 
is quite different in South-East Asia where tuberculosis 
has always been prevalent in the general population. For 
instance, 26% of new cases of tuberculosis in the United 
States are attributable to HIV infection[1], whereas the 
corresponding figures for India, Pakistan and Bangladesh 
are only 5.0%, 0.3% and 0.2% respectively[21,23]. This is 
not unsurprising as the combined burden of new cases of 
tuberculosis in these three countries is 3 001 093[22,23], with 
the majority of patients being HIV-seronegative. In such a 
scenario, it is essential to determine whether tuberculosis in 
a given HIV-positive individual is really due to underlying 
immunosuppression or whether it is purely incidental. 
A blanket diagnosis of AIDS in HIV-positive individuals 
with tuberculosis would require that even HIV-positive 
individuals with incidental tuberculosis be put on ART for 
life-not a cost-effective approach especially in resource-
constrained settings. This point is highlighted by our finding 
that over 7% of HIV-positive individuals with tuberculosis 
had CD4 counts greater than 200 cells/毺L, indicating that 
it was not compelling to otherwise start ART in them. It is 
therefore imperative that tuberculosis should be reclassified 
from a category C to category B condition or that at least, 
tuberculosis should not be considered grounds for initiation 
of ART in the absence of corroborative low CD4 counts, in 
countries with high prevalence of tuberculosis.
  This study shows that the presence of accompanying 
evidence of immunosuppression in the form of category B 
and C conditions in the HIV-positive patients with active 
tuberculosis is associated with significantly lower CD4 count; 
counter-intuitively, severe forms of tuberculosis are not 
necessarily associated with lower CD4 counts. This finding 
Table 3
CD4 counts across patients according to severity and form of tuberculosis.
Patient Form of tuberculosis Number of patients Patient percentage (%) CD4 count
Mild tuberculosis Pulmonary parenchymal tuberculosis 39 27.9  84.5依85.0
Tubercular lymphadenitis 35 25.0  91.4依87.7
Tubercular effusion   7   5.0  108.7依103.4
Tubercular peritonitis   3   2.1  77.3依18.0
Severe tuberculosis Disseminated tuberculosis 39 27.9  84.5依79.4
Tubercular meningitis   8   5.7  77.6依65.2
Tuberculoma   5   3.6  59.4依38.9
Miliary tuberculosis   3   2.1 115.7依50.7
Tubercular pericarditis   1   0.7   7.0
Table 4
Comparison of baseline characteristics and CD4 counts across patients with different severity of tuberculosis
Tuberculosis Age (years) Male-to-female ratio CD4 count (cells/毺L)
Mild tuberculosis (n=84) 40.1依9.2 68:16 89.1依85.3
Severe tuberculosis (n=56) 39.8依7.7 41:15 81.6依72.9
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emphasizes the need to carefully search for such co-existing 
conditions in these patients, and not to simply focus on the 
form of tuberculosis. Certainly, patients with concomitant 
category B and C conditions are likely to have a more 
advanced infection with HIV and therefore have poorer long-
term outcomes, even when compared to patients with severe 
tuberculosis without such conditions. Incorporating such 
an approach at the time of dealing with HIV-tuberculosis 
co-infected patients would grant the treating physician a 
better perspective of the degree of immunosuppression and 
correspondingly the need for initiation of ART.
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